Stock Events

Stock Events

Inhibrx Biosciences 

$90.64
17
-$2.57-2.76% 16:31 Today

Statistics

Day High
94.49
Day Low
90
52W High
155.29
52W Low
20.55
Volume
3,511,707
Avg. Volume
-
Mkt Cap
1.33B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.38
-2.81
-2.24
-1.68
Expected EPS
-2.28
Actual EPS
N/A

Financials

-10,773.46%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.3MRevenue
-140.06MNet Income

Analyst Ratings

150.00Average Price Target
The highest estimate is 150.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INBX. It's not an investment recommendation.
Palantir Technologies
4
PLTR
Tesla
3
TSLA
Carnival
3
CCL
Apple
2
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes in the biotechnology field focusing on immunology and oncology, similar to Inhibrx's focus areas.
AMGEN
AMGN
Mkt Cap196.12B
Amgen operates in the same biopharmaceutical sector, developing therapies in areas like oncology, which overlaps with Inhibrx's pipeline.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas including oncology, directly competing with Inhibrx.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb offers a range of cancer treatments, competing in the oncology space with Inhibrx.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. is a global healthcare company that produces cancer drugs and vaccines, making it a competitor in the oncology field.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a large pharmaceutical company with a broad portfolio that includes oncology and immunology drugs, competing with Inhibrx.
Novartis
NVS
Mkt Cap293.94B
Novartis AG focuses on patented medicines for a range of diseases, including cancer, directly competing with Inhibrx's research and development in oncology.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG specializes in biotechnology products for oncology, among other areas, making it a competitor in the same field as Inhibrx.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca PLC operates in various therapeutic areas, including oncology, competing with Inhibrx in the development of cancer treatments.

About

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Show more...
CEO
Mr. Mark Paul Lappe
Employees
109
Country
United States
ISIN
US45720N1037

Listings

XNAS
US
INBX
BOATS
BOATS
INBX.BOATS

0 Comments

Share your thoughts

FAQ

What is Inhibrx Biosciences stock price today?▼
The current price of INBX is $90.64 USD — it has decreased by -2.76% in the past 24 hours. Watch Inhibrx Biosciences stock price performance more closely on the chart.
What is Inhibrx Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Inhibrx Biosciences stocks are traded under the ticker INBX.
Is Inhibrx Biosciences stock price growing?▼
INBX stock has fallen by -7.27% compared to the previous week, the month change is a -3.71% fall, over the last year Inhibrx Biosciences has showed a +292.16% increase.
What is Inhibrx Biosciences market cap?▼
Today Inhibrx Biosciences has the market capitalization of 1.33B
When is the next Inhibrx Biosciences earnings date?▼
Inhibrx Biosciences is going to release the next earnings report on August 19, 2026.
What were Inhibrx Biosciences earnings last quarter?▼
INBX earnings for the last quarter are -2.15 USD per share, whereas the estimation was -1.68 USD resulting in a -28.36% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inhibrx Biosciences revenue for the last year?▼
Inhibrx Biosciences revenue for the last year amounts to 1.3M USD.
What is Inhibrx Biosciences net income for the last year?▼
INBX net income for the last year is -140.06M USD.
How many employees does Inhibrx Biosciences have?▼
As of July 15, 2026, the company has 109 employees.
In which sector is Inhibrx Biosciences located?▼
Inhibrx Biosciences operates in the Health & Wellness sector.
When did Inhibrx Biosciences complete a stock split?▼
Inhibrx Biosciences has not had any recent stock splits.
Where is Inhibrx Biosciences headquartered?▼
Inhibrx Biosciences is headquartered in La Jolla, United States.